Press release - 22/05/2025 Six Clusters of Excellence for the University of Tübingen Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support.https://www.gesundheitsindustrie-bw.de/en/article/press-release/six-clusters-excellence-university-tubingen
Press release - 13/05/2025 Award for Outstanding Contributions to Cancer Research Dr Dr Varun Venkataramani and Dr Moritz Mall have been awarded this year’s Hella Bühler Prize for their outstanding research on the interaction between nerve and tumor cells and on tumor plasticity. The award granted by Heidelberg University goes to young researchers from the Heidelberg research location who have already drawn attention to themselves through the outstanding scientific quality of their cancer research. https://www.gesundheitsindustrie-bw.de/en/article/press-release/award-outstanding-contributions-cancer-research
Press release - 08/05/2025 Childhood brain tumors develop early in highly specialized nerve cells Medulloblastomas, childhood brain tumors in children, are thought to develop between the first trimester of pregnancy and the end of the first year of life. Researchers have now published their findings in the journal Nature. They analyzed the genetic changes of each individual cancer cell in tumor samples in order to reconstruct which genetic changes occur first during tumor development and when.https://www.gesundheitsindustrie-bw.de/en/article/press-release/childhood-brain-tumors-develop-early-highly-specialized-nerve-cells
Press release - 07/04/2025 Interdisciplinary research to provide urgently needed insecticides to combat malaria The Medical Faculty Heidelberg of Heidelberg University and Mannheim University of Applied Sciences are combining their expertise in infectious disease research, mass spectrometry, and bioinformatics to overcome resistance in malaria vectors. The project is supported by funding from the Gates Foundation.https://www.gesundheitsindustrie-bw.de/en/article/press-release/interdisciplinary-research-provide-urgently-needed-insecticides-combat-malaria
Press release - 02/04/2025 New antibiotic for multidrug resistant superbug Researchers from the universities in Konstanz and Vienna discover a new class of antibiotic that selectively targets Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. These substances trigger a self-destruction program, which also operates in multi-resistant variants of the pathogen. The novel findings are published in the current issue of Nature Microbiology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-antibiotic-multidrug-resistant-superbug
Press release - 24/03/2025 Resistance mechanism in chronic lymphocytic leukemia identified Researchers at the German Cancer Research Center (DKFZ) have succeeded in identifying a resistance mechanism that often occurs in a specific targeted therapy against chronic lymphocytic leukemia (CLL). The drug ibrutinib is effective in many cases, but therapy resistance often develops during the course of treatment. In cell culture experiments and in mice, the resistance mechanism was successfully overcome using a second drug.https://www.gesundheitsindustrie-bw.de/en/article/press-release/resistance-mechanism-chronic-lymphocytic-leukemia-identified
Press release - 19/03/2025 Pocket-sized breath test for stomach bacteria Mini sensor analyses breath for infection with Helicobacter pylori Stomach ulcers, gastritis and even stomach cancer are often the result of an infection with Helicobacter pylori. If the bacterium remains unrecognised for a long time, this can have serious consequences. Researchers have now developed a miniaturisable sensor system for the mobile analysis of breath that is effective, fast and inexpensive. The research team uses a biological survival trick of the stomach germ to detect the bacterium. https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-breath-test-stomach-bacteria-mini-sensor-analyses-breath-infection-helicobacter-pylori
Press release - 14/03/2025 Tool identifies specific viruses to combat dangerous bacteria University of Tübingen research team shortens the search for attackers that can wipe out multiresistant pathogens – with the aim of treating infections without antibioticshttps://www.gesundheitsindustrie-bw.de/en/article/press-release/tool-identifies-specific-viruses-combat-dangerous-bacteria
Press release - 05/03/2025 Frank Winkler receives the Brain Prize 2025 This year, the Brain Prize worth more than one million euros, honors pioneering work on nervous system-cancer interactions: Neurologist Frank Winkler, who researches at the Heidelberg University and at the German Cancer Research Center and treats patients with brain tumors at the Heidelberg University Hospital, discovered that nerve cells in the brain communicate with brain tumor cells. This causes the disease to progress.https://www.gesundheitsindustrie-bw.de/en/article/press-release/frank-winkler-receives-brain-prize-2025
Press release - 10/02/2025 Medical textiles with infection protection In collaboration with Heraeus, the German Institutes of Textile and Fiber Research (DITF) are developing fibers and textiles with a novel infection protection system. The basis is an antimicrobial mechanism of action licensed from Heraeus and marketed under the name AGXX. The goal of the collaboration is to optimally integrate the AGXX technology into textile finishes and coatings and to incorporate it into fiber-spinnable polymers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/medical-textiles-infection-protection
Press release - 03/01/2025 New approaches against metastatic breast cancer: mini-tumors from circulating cancer cells Tumor cells circulating in the blood are the "germ cells" of breast cancer metastases. They are rare and could not be propagated in the culture dish until now, which made research into therapy resistance difficult. A team from the DKFZ, the Heidelberg Stem Cell Institute HI-STEM and the NCT Heidelberg has now succeeded for the first time in cultivating stable tumor organoids directly from blood samples of breast cancer patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-against-metastatic-breast-cancer-mini-tumors-circulating-cancer-cells
Press release - 25/11/2024 Chromosomal chaos promotes therapy resistance in leukemia cells and opens up new treatment approaches Chromosomal instability plays a role in the progression of cancer: it shapes the properties of tumor cells and drives the development of therapy resistance. Scientists from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM* and the European Molecular Biology Laboratory (EMBL) used state-of-the-art single-cell analysis methods to analyze the cellular heterogeneity of a specific form of acute myeloid leukemia. https://www.gesundheitsindustrie-bw.de/en/article/press-release/chromosomal-chaos-promotes-therapy-resistance-leukemia-cells-and-opens-new-treatment-approaches
Sustainable medical technology - 10/10/2024 Rethinking plastics in medical technology Good healthcare relies heavily on medical products made from plastic. However, the widespread use of synthetic materials, particularly disposable items, creates vast amounts of waste, depletes resources and leads to a substantial carbon footprint. To create more environmentally friendly plastic products in the future, substantial changes to production processes are essential.https://www.gesundheitsindustrie-bw.de/en/article/news/rethinking-plastics-medical-technology
Press release - 19/09/2024 Quality standards for looking into the tumor genome Personalized medicine with individually tailored therapies is becoming more a reality in cancer. This requires a look into the genetic material of tumors, a molecular diagnostic tumor profile. A research group from the German Network for Personalized Medicine (DNPM) has recorded the quality standards according to which genome analyses are carried out in Germany. The data is a prerequisite for integrating gene sequencing into routine care. https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-standards-looking-tumor-genome
App for tuberculosis diagnosis - 15/05/2024 "Find-TB" aims to improve access to tuberculosis diagnostics Globally, the majority of children with tuberculosis remain undiagnosed and therefore untreated because their symptoms are categorised incorrectly. Researchers at Heidelberg University Hospital want to develop an app that analyses medical information, risk factors and local surveillance data to calculate individual risk of infection and test those who might be affected with TB as early as possible.https://www.gesundheitsindustrie-bw.de/en/article/news/find-tb-aims-improve-access-tuberculosis-diagnostics
Press release - 13/05/2024 Detecting respiratory infections: simply blow for diagnosis Professor Claudia Denkinger from Heidelberg University's Faculty of Medicine is leading the international collaborative project "BreathForDiagnosis". Researchers from Germany, Italy, South Africa and Romania are working with an industrial partner from Switzerland to develop user-friendly breath tests for the rapid diagnosis of respiratory infections such as tuberculosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/detecting-respiratory-infections-simply-blow-diagnosis
Press release - 07/05/2024 Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development. https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects
Press release - 19/04/2024 Electrified bacteria PhD student at Furtwangen University develops method for faster determination of antibiotic resistance. The increase in antibiotic-resistant pathogens and the associated treatment, which is a major problem in public healthcare facilities, is the subject of a research project at Furtwangen University.https://www.gesundheitsindustrie-bw.de/en/article/press-release/bakterien-unter-strom
Press release - 18/04/2024 Additional partnership in medical technology: Bosch and R-Biopharm to strengthen Vivalytic analysis platform The market for medical technology is innovative, dynamic, and growing. Bosch sees medical technology as a strategic growth field and intends to expand its Bosch Healthcare Solutions subsidiary, based in Waiblingen. Bosch has now entered into a new partnership with the German diagnostics solutions company R-Biopharm. This partnership will be focused on Bosch’s universal, fully automated Vivalytic molecular diagnostic analysis platform. https://www.gesundheitsindustrie-bw.de/en/article/press-release/additional-partnership-medical-technology-bosch-and-r-biopharm-strengthen-vivalytic-analysis-platform
Epifadin from the nasal microbiome - 28/03/2024 From the nose: novel antibiotic substance discovered Antibiotics are becoming an increasingly blunt weapon against infectious diseases. The number of (multi-)resistant germs has been rising rapidly for years and even reserve antibiotics no longer work. Researchers at the University of Tübingen have now isolated a completely new antibiotic substance called epifadin from the microbiome of the human nose. It is effective against many different bacteria - including the dangerous hospital MRSA.https://www.gesundheitsindustrie-bw.de/en/article/news/nose-novel-antibiotic-substance-discovered
Stem cell research - 14/03/2024 Using organoids to gain a better clinical understanding of pancreatic cancer Prof. Dr. Alexander Kleger carries out translational research at Ulm University Hospital to gain a better understanding of pancreatic ductal adenocarcinoma (PDAC) and develop individualised treatments. He and his team are using organoid models and stem cell-based systems and have succeeded in simultaneously cultivating all three main cell types of the pancreas from pluripotent stem cells.https://www.gesundheitsindustrie-bw.de/en/article/news/using-organoids-gain-better-clinical-understanding-pancreatic-cancer
Press release - 05/03/2024 New Center for Synthetic Genomics Applying and developing new technologies for DNA synthesis to pave the way for producing entire artificial genomes – that is the goal of a new interdisciplinary center, 'Center for Synthetic Genomics', that is being established at Heidelberg University, Karlsruhe Institute of Technology (KIT), and Johannes Gutenberg University Mainz (JGU). https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-center-synthetic-genomics
Press release - 05/01/2024 Prostate cancer: Newly-developed inhibitor shows massive potential More than 65,000 men fall ill with prostate cancer each year in Germany. Twelve thousand of them develop a treatment-resistant form which eventually ends in death. Now, a team of researchers from the Medical Faculty at the University of Freiburg has developed an active substance that might in future represent a new treatment option. https://www.gesundheitsindustrie-bw.de/en/article/press-release/prostate-cancer-newly-developed-inhibitor-shows-massive-potential
Press release - 03/01/2024 Reprogrammed fat cells support tumor growth Mutations of the tumor suppressor p53 not only have a growth-promoting effect on the cancer cells themselves, but also influence the cells in the tumor's microenvironment. Scientists at the Weizmann Institute in Israel and at the German Cancer Research Center (DKFZ) have now shown that p53-mutated mouse breast cancer cells reprogram fat cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/reprogrammed-fat-cells-support-tumor-growth
Press release - 18/12/2023 Researchers discover novel antibiotic substance from the human nose For the first time, the active substance epifadin has been isolated at the University of Tübingen – Epifadin is produced by specific bacteria in the nose and on the skin of humans, has an antibiotic effect, and is the first example of a previously unknown antimicrobial compound class.https://www.gesundheitsindustrie-bw.de/en/article/press-release/researchers-discover-novel-antibiotic-substance-human-nose
All-enzyme hydrogels in action - 13/12/2023 Biocatalytic foams enable the sustainable synthesis of complex molecules Conventional chemical synthesis processes consume large amounts of energy and environmentally harmful solvents. Prof. Dr. Christof Niemeyer’s team at the Karlsruhe Institute of Technology has generated porous, solid foams from crosslinked enzymes that allow the production of high-quality compounds under significantly more environmentally friendly conditions. The novel biocatalysts are also extremely resistant and have a long shelf life.https://www.gesundheitsindustrie-bw.de/en/article/news/biocatalytic-foams-enable-sustainable-synthesis-complex-molecules
Computer-assisted genome mining - 04/12/2023 Natural product genomics opens up new avenues in the search for antibiotics Antibiotic-resistant pathogens are increasingly endangering our health. Since most of the drugs currently in use are based on secondary metabolites produced by bacteria or fungi, the research group of Prof. Dr. Nadine Ziemert in Tübingen is developing bioinformatic tools to specifically search the genome of these organisms for previously unknown antimicrobial agents.https://www.gesundheitsindustrie-bw.de/en/article/news/natural-product-genomics-opens-new-avenues-search-antibiotics
Press release - 30/11/2023 Taking antibiotics back in time University of Tübingen researchers reverse the evolution of a class of antibiotics to gain insights for the development of new drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/taking-antibiotics-back-time
Press release - 15/11/2023 Nanoparticles for optimized cancer therapy Pancreatic cancer is one of the deadliest types of cancers in humans. Chemotherapies attack not only the tumor cells but also healthy cells throughout the body. Innovative nanoparticles could be a new approach to treat cancer more precisely. The approach was developed by a research team from the Max Planck Institute (MPI) for Multidisciplinary Sciences, the University Medical Center Göttingen (UMG), and the Karlsruhe Institute of Technology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanopartikel-fuer-optimierte-krebstherapie
Press release - 10/11/2023 Therapy resistance in multiple myeloma: molecular analyses of individual cancer cells reveal new mechanisms All cancer cells - even those within the same tumor - differ from each other and change over the course of a cancer disease. Scientists at Heidelberg University Hospital, the Medical Faculty in Heidelberg and the German Cancer Research Center discovered molecular changes in multiple myeloma that help individual cancer cells to survive therapy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapy-resistance-multiple-myeloma-molecular-analyses-individual-cancer-cells-reveal-new-mechanisms
Nanoparticles as drug carriers - 09/11/2023 Inhalation of nanocarriers for antibiotics against resistant tuberculosis pathogens Around ten million people worldwide still contract tuberculosis every year. With an estimated 1.4 million deaths a year, tuberculosis was the world’s deadliest infectious disease until COVID-19. The high mortality rate is down to the sophisticated biology of the pathogen Mycobacterium tuberculosis. A team of researchers from the KIT and the Research Centre Borstel (FZB) has developed a method that aims to outsmart the bacterium once and for all.https://www.gesundheitsindustrie-bw.de/en/article/news/inhalation-nanocarriers-antibiotics-against-resistant-tuberculosis-pathogens
Press release - 18/10/2023 SARS-CoV-2: Alert immune system in the respiratory tract protects children from severe courses of the disease Why are severe courses of SARS-CoV-2 infection less common in children and adolescents than in adults? Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the immune system in the upper respiratory tract is much more alert and active in children before infection than in adults and is therefore better equipped to fight the virus.https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-aktiveres-immunsystem-den-atemwegen-schuetzt-kinder-vor-schweren-verlaeufen
Press release - 19/09/2023 Better distinguish chronic inflammation and cancer of the pancreas Current diagnostic methods do not always reliably distinguish between chronic inflammation of the pancreas and pancreatic cancer. About one third of all diagnoses are inconclusive. Scientists from the German Cancer Research (DKFZ) and from Heidelberg University Hospital (UKHD) therefore searched for molecular markers that could specify this diagnosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/chronische-entzuendung-und-krebs-der-bauchspeicheldruese-praeziser-unterscheiden
Press release - 20/06/2023 Tuberculosis Therapy: Smallest Particles Will Deliver the Drug to the Lungs in Future KIT and Research Center Borstel Present Nanoparticles with a High Antibiotic Concentration for Inhalation – Nanocarriers of Antibiotics Can Reduce Resistances and Enhance Compatibility.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tuberculosis-therapy-smallest-particles-will-deliver-drug-lungs-future
Detecting drug resistance of tumour cells - 25/05/2023 AI-assisted diagnostics declares war on lung cancer Lung cancer is one of the most common cancers and has a particularly high mortality rate. A significant challenge in treating this disease lies in the resistance of lung tumours to conventional drug therapies, rendering chemotherapy ineffective. There is hope on the horizon as a team of experts from Baden-Württemberg has joined forces to develop an innovative AI-supported test procedure that paves the way for individualised therapy approaches.https://www.gesundheitsindustrie-bw.de/en/article/news/ai-assisted-diagnostics-declares-war-lung-cancer
Press release - 16/05/2023 Mast cells have an important impact on the development of chronic myeloid leukemia Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20 percent of all adult leukemia cases. A research team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg has now demonstrated for the first time that mast cells play a crucial role in the development of CML.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mast-cells-have-important-impact-development-chronic-myeloid-leukemia
Press release - 06/04/2023 Alternative glucose breakdown ensures the survival of cancer cells A key enzyme in sugar metabolism is inactivated particularly easily and efficiently by oxidative stress. Scientists at the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now shown that with this oxidation, cells switch to an alternative sugar breakdown pathway and can thus escape oxidative stress. Cancer cells in particular benefit from this mechanism, which can also protect them from therapy-related damage.https://www.gesundheitsindustrie-bw.de/en/article/press-release/alternative-glucose-breakdown-ensures-survival-cancer-cells
Press release - 23/03/2023 Targeted computer modelling to accelerate antiviral drug development Effective drugs against viral diseases like COVID-19 are urgently needed now and in the future. The emergence of viral mutants and yet unknown viruses could push vaccines to their limits. The DZIF scientist and bioinformatician Andreas Dräger from the University of Tübingen is working on a computer-based method that can help to accelerate the time-consuming identification and development of antiviral agents. Using a novel analysis technique that…https://www.gesundheitsindustrie-bw.de/en/article/press-release/computermodellierung-zur-schnelleren-entwicklung-antiviraler-medikamente
Press release - 01/03/2023 Pseudomonas aeruginosa Bacteria produce a molecule that paralyzes immune system cells Bacteria of the species Pseudomonas aeruginosa are antibiotic-resistant hospital germs that can enter blood, lungs and other tissues through wounds and cause life-threatening infections. In a joint project, researchers from the Universities of Freiburg and Strasbourg in France have discovered a mechanism that likely contributes to the severity of P. aeruginosa infections.https://www.gesundheitsindustrie-bw.de/en/article/press-release/pseudomonas-aeruginosa-bakterien-stellen-ein-molekuel-her-das-zellen-des-immunsystems-laehmt
Press release - 17/01/2023 Sugar-based inhibitors disarm the pathogen Pseudomonas aeruginosa The hospital pathogen Pseudomonas aeruginosa requires the sugar-binding proteins LecA and LecB to form biofilms as well as to attach to and penetrate host cells. These so-called lectins are therefore suitable targets for active substances to combat Pseudomonas infections. Researchers from Saarbrücken and Freiburg have now produced potent inhibitors for LecA and LecB that are more stable and soluble than previous drug candidates.https://www.gesundheitsindustrie-bw.de/en/article/press-release/zuckerbasierte-inhibitoren-entwaffnen-den-krankheitserreger-pseudomonas-aeruginosa
Press release - 24/11/2022 SARS-CoV-2 detection in 30 minutes using gene scissors Researchers of the University of Freiburg introduce biosensor for the nucleic acid amplification-free detection of SARS-CoV-2 RNA. https://www.gesundheitsindustrie-bw.de/en/article/press-release/sars-cov-2-nachweis-30-minuten-mit-der-genschere
Press release - 09/11/2022 New Molecular Microscopy Uncovers how Breast Cancer Spreads Researchers have created a tool that maps how breast cancer grows in previously unseen detail, and highlights how the cells around the tumour may be the key to controlling the spread of disease. The new technology can trace which populations of breast cancer cells are responsible for the spread of the disease, and for the first time highlights how the location of cancer cells could be as important as mutations in tumor growth The new study is…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-microscopy-uncovers-how-breast-cancer-spreads
Press release - 02/11/2022 The guardian of the (epi-)genome Toxicologists from the University of Konstanz have found that the protein p53 continuously protects our cells from tumorigenesis by coordinating important metabolic processes that stabilize their genomes.https://www.gesundheitsindustrie-bw.de/en/article/press-release/guardian-epi-genome
Press release - 24/10/2022 How tumors suppress the development of metastases Why do metastases often only appear after the original tumor has been surgically removed? Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim Medical Faculty of Heidelberg University have now published an explanation for this phenomenon. They were able to identify a messenger substance of the cancer cells that locally promotes the growth of the primary tumor.https://www.gesundheitsindustrie-bw.de/en/article/press-release/wie-tumoren-die-entstehung-von-metastasen-unterdruecken
Press release - 20/10/2022 Cytoskeleton acts as cells’ bouncer for bacteria Researchers of the University of Freiburg have discovered a previously unknown function of septins in defending cells against dangerous hospital pathogens.https://www.gesundheitsindustrie-bw.de/en/article/press-release/das-zellskelett-haelt-die-eintrittspforte-fuer-bakterien-geschlossen
Press release - 19/09/2022 How stressed tumor cells escape cell death: new mechanism discovered Because of their highly active metabolism, many tumors are susceptible to a special type of cell death, ferroptosis. Nevertheless, cancer cells often manage to escape this fate. Scientists at the German Cancer Research Center have now discovered a new mechanism by which normal as well as cancer cells protect themselves against ferroptosis.https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-stressed-tumor-cells-escape-cell-death-new-mechanism-discovered
Press release - 01/09/2022 Personalised antibiotic treatment strategies for tuberculosis patients Tuberculosis is one of the leading causes of death worldwide, with an estimated 1.4 million deaths and ten million people infected annually. Resistant and multidrug-resistant (MDR) variants of the tuberculosis pathogen Mycobacterium tuberculosis pose a major threat to tuberculosis control and global health.https://www.gesundheitsindustrie-bw.de/en/article/press-release/personalisierte-antibiotika-behandlungsstrategie-bei-tuberkulose-erkrankten
Bakteriocins - 24/05/2022 New antibiotic alternatives from soil bacteria Bacteria are not the greatest of friends among themselves: many release antimicrobial substances into their environment in order to gain an advantage in their ecological niche. Researchers at the University of Ulm are making use of such bacteriocins by creating a genetically modified soil bacterium that can be used as a biotechnological platform organism to produce alternatives to antibiotics in pure form and in large quantities. The fact this…https://www.gesundheitsindustrie-bw.de/en/article/news/new-antibiotic-alternatives-soil-bacteria
Press release - 28/04/2022 Tumors on withdrawal: Amino acid deficiency shrinks childhood tumors Certain childhood tumors have an extreme need for amino acids. Scientists at the Hopp Children's Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), the University of Heidelberg, and HI-STEM* gGmbH have now discovered the molecular mechanisms underlying this and how the cancer cells could be turned off.https://www.gesundheitsindustrie-bw.de/en/article/press-release/tumors-withdrawal-amino-acid-deficiency-shrinks-childhood-tumors
Press release - 13/04/2022 Emmy Noether funding for research into drug resistance of blood cancer The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is funding a new Emmy Noether junior research group at the DKFZ for six years with a total of around 2 million euros. The scientists and doctors, who are part of the Clinical Cooperation Unit for Pediatric Leukemia at the KiTZ, are using a new procedure to investigate how cancer cells manipulate the formation of proteins to become resistant to cancer drugs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/emmy-noether-funding-research-drug-resistance-blood-cancer